As part of a comprehensive review of the companys future strategy and operations, BristolMyersSquibb will be focusing on innovative products for unmet medical needs and, in the process, will rationalize its portfolio of existing products.

Despite our efforts to continue to make BiCNU available locally, a global decision has been made that BiCNU injection - carmustine lyophilized powder - 100mg vial and dehydrated alcohol for reconstitution will be discontinued in the near future. We anticipate that the stock levels of BiCNU will be depleted by the end of 2009, whereafter no replacement stock will be available.

Back to the Bulletin Board